07.14.09
Money may be tight right now, but that's not stopping one private equity firm from putting a new wrinkle in the global anti-aging market. Catterton Partners, has acquired the StriVectin brand from Klein-Becker for an undisclosed amount. The brand will be managed by Chrysallis, a beauty industry-focused management team.
StriVectin is estimated to generate $100 million in retail sales, and is carried in Macy’s, Bloomingdale’s, Sephora, Ulta and CVS Pharmacy’s Beauty 360 doors. Products in the line include Instant Facial Sculpting Cream, SD Eye Cream, Neck Cream and WF Instant Deep Wrinkle Filler.
Under Chrysallis, which is led by chief executive officer Melisse Shaban and chief marketing officer Jill Scalamandre, the StriVectin brand will be broadened into multiple antiaging platforms and categories, and expanded internationally.
StriVectin is estimated to generate $100 million in retail sales, and is carried in Macy’s, Bloomingdale’s, Sephora, Ulta and CVS Pharmacy’s Beauty 360 doors. Products in the line include Instant Facial Sculpting Cream, SD Eye Cream, Neck Cream and WF Instant Deep Wrinkle Filler.
Under Chrysallis, which is led by chief executive officer Melisse Shaban and chief marketing officer Jill Scalamandre, the StriVectin brand will be broadened into multiple antiaging platforms and categories, and expanded internationally.